Leerink Partners analyst Marc Goodman maintains $Biogen (BIIB.US)$ with a buy rating, and adjusts the target price from $310 to $290.
According to TipRanks data, the analyst has a success rate of 48.6% and a total average return of 6.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
The company's product launches continue to face challenges amidst intensifying competition, with significant pipeline catalysts anticipated to emerge in 2026 and beyond.
The launch of Leqembi has not met initial expectations, and there appears to be limited opportunities for new developments in the company's pipeline over the coming year. There was an underestimation of the initial challenges related to reimbursement and logistics for Leqembi. The perspective for Biogen now involves a balanced risk/reward scenario and a cautious forecast for lecanemab.
Biogen's third-quarter financial performance was noted to be robust, with total revenues surpassing expectations and adjusted earnings per share also beating consensus estimates. The company's sales of Leqembi are seen as outperforming, indicating vigorous momentum in the development of its infrastructure. It is expected that the intravenous maintenance and subcutaneous formulations will greatly enhance adoption rates by 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Leerink Partners分析師Marc Goodman維持$渤健公司 (BIIB.US)$買入評級，並將目標價從310美元下調至290美元。
根據TipRanks數據顯示，該分析師近一年總勝率為48.6%，總平均回報率為6.6%。
此外，綜合報道，$渤健公司 (BIIB.US)$近期主要分析師觀點如下：
公司的產品推出在日益激烈的競爭中持續面臨挑戰，預計2026年及以後將出現重要的管道催化劑。
Leqembi的推出未能達到最初的預期，公司管道中在未來一年內似乎面臨有限的新發展機會。最初低估了Leqembi在退款和物流方面的挑戰。Biogen的展望現在涉及到一個平衡的風險/回報情景，以及對lecanemab的謹慎預測。
渤健公司第三季度財務表現強勁，總收入超過預期，調整後的每股收益也超過共識估計。公司Leqembi的銷售被視爲表現優異，表明其製造行業發展勢頭強勁。預計到2025年，靜脈維護和皮下配方將大大提高採納率。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
